You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Epstein–Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis
|
|---|---|
| Published in |
Multiple Sclerosis Journal, February 2014
|
| DOI | 10.1177/1352458514521888 |
| Pubmed ID | |
| Authors |
Michael P Pender, Peter A Csurhes, Corey Smith, Leone Beagley, Kaye D Hooper, Meenakshi Raj, Alan Coulthard, Scott R Burrows, Rajiv Khanna |
| Abstract |
Defective control of Epstein-Barr virus (EBV) infection by cytotoxic CD8(+) T cells might predispose to multiple sclerosis (MS) by allowing EBV-infected autoreactive B cells to accumulate in the central nervous system. We have treated a patient with secondary progressive MS with in vitro-expanded autologous EBV-specific CD8(+) T cells directed against viral latent proteins. This adoptive immunotherapy had no adverse effects and the patient showed clinical improvement with reduced disease activity on magnetic resonance imaging and decreased intrathecal immunoglobulin production. This is the first report of the use of EBV-specific adoptive immunotherapy to treat MS or any other autoimmune disease. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 3 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 3 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 95 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Unknown | 94 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 14% |
| Researcher | 11 | 12% |
| Other | 10 | 11% |
| Student > Doctoral Student | 9 | 9% |
| Student > Ph. D. Student | 9 | 9% |
| Other | 15 | 16% |
| Unknown | 28 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 25% |
| Neuroscience | 7 | 7% |
| Biochemistry, Genetics and Molecular Biology | 6 | 6% |
| Immunology and Microbiology | 6 | 6% |
| Chemistry | 5 | 5% |
| Other | 15 | 16% |
| Unknown | 32 | 34% |
Attention Score in Context
This research output has an Altmetric Attention Score of 53. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 October 2022.
All research outputs
#806,718
of 25,504,429 outputs
Outputs from Multiple Sclerosis Journal
#77
of 3,727 outputs
Outputs of similar age
#8,545
of 323,445 outputs
Outputs of similar age from Multiple Sclerosis Journal
#1
of 73 outputs
Altmetric has tracked 25,504,429 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,727 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.2. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,445 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 97% of its contemporaries.
We're also able to compare this research output to 73 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.